AVITA Medical (AVHHL) Cash & Equivalents (2018 - 2025)

AVITA Medical has reported Cash & Equivalents for 8 years, with the latest figure at $10.2 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 27.1% year-over-year to $10.2 million; the trailing twelve-month figure through Dec 2025 stood at $10.2 million (down 27.1% YoY), and the FY2025 full-year result was $10.2 million, down 27.1% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $10.2 million, up from $8.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $115.1 million in Q1 2021, with the low at $8.3 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $32.7 million across 5 years, with a median of $17.4 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 85.58% — and 2023, when it soared 192.26%.
• AVITA Medical's Cash & Equivalents stood at $55.7 million in 2021, then slumped by 67.4% to $18.2 million in 2022, then plunged by 37.24% to $11.4 million in 2023, then advanced by 23.25% to $14.0 million in 2024, then decreased by 27.1% to $10.2 million in 2025.
• The last three Cash & Equivalents figures came in at $10.2 million (Q4 2025), $8.3 million (Q3 2025), and $10.6 million (Q2 2025), per Business Quant data.